A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of ABT-335 [choline-fenofibrate] in combination with atorvastatin and ezetemibe to atorvastatin in combination with ezetimibe in subjects with combined (atherogenic) dyslipidemia
Latest Information Update: 25 Sep 2021
At a glance
- Drugs Choline fenofibrate (Primary) ; Atorvastatin; Ezetimibe
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 11 Dec 2008 Actual initiation date changed from Mar 2008 to Feb 2008 as reported by ClinicalTrials.gov.
- 11 Dec 2008 Planned number of patients changed from 460 to 543 as reported by ClinicalTrials.gov.
- 11 Dec 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.